Electromed, Inc. Earnings Recaps
Q3 2026
May 13, 2026
Electromed’s Q3 results surpassed expectations, driving a 31.2% stock rally, powered by broad-based revenue growth, significant margin expansion, and strong execution in both commercial and clinical initiatives.
Key takeaways
- Revenue grew 18.4% year-over-year to $18.6 million, supported by a 19% increase in Home Care and a 43% rebound in Hospital sales.
- Operating income surged 76% to $3.8 million, reflecting meaningful margin improvement.
- Diluted EPS rose 67% to $0.35, marking continued profitability gains.
- The company advanced adoption with over 40% of orders through its Smart Order ePrescribe system, shortening shipment times by 5 days.
- Clinical education efforts and the Triple Down on Bronchiectasis campaign are driving awareness in a large underpenetrated patient market.
Q2 2026
Feb 11, 2026
Electromed, Inc. delivered a standout performance in Q2 FY 2026 with record revenue of $18.9 million, marking the thirteenth consecutive quarter of revenue and profit growth, despite a strategic pullback in hospital shipments.
Key takeaways
- Revenue increased by 16.3% year-over-year, driven by an 18.4% rise in the Home Care segment.
- Operating income grew 42.4% year-over-year to $3 million, with an operating income margin of 19%.
- The "Triple Down on Bronchiectasis" campaign launched to target a significant unmet need in bronchiectasis care, addressing potential expansion to 800,000 underserved patients.
- 25 new payer contracts were secured, expanding coverage to an additional 2.9 million lives, enhancing market access for SmartVest.
- Implementation of digital solutions, including the Smart Order e-prescribe, streamlined order fulfillment, with over one-third of orders now processed through this platform.